Sinew Pharma Inc.
Taipei Exchange 6634.TWO
Sinew Pharma Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -19.21
-
Sinew Pharma Inc. 52-week high Price to Earnings Ratio (P/E) is -17.97 on December 20, 2024, which is 6.43% above the current Price to Earnings Ratio (P/E).
-
Sinew Pharma Inc. 52-week low Price to Earnings Ratio (P/E) is -31.19 on June 05, 2024, which is -62.37% below the current Price to Earnings Ratio (P/E).
-
Sinew Pharma Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -24.55.
| Date | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield |
|---|
| CEO | Dr. Kai-Min Chu M.D., Ph.D. |
| IPO Date | June 30, 2017 |
| Location | |
| Headquarters | C516, Building C |
| Employees | 51 |
| Sector | Health Care |
| Industries | |
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630, a pre-clinical drug for treating patients with non-alcoholic steatohepatitis. It is also developing SNP-810 for use in analgesic and antipyretic indications; and SNP-830 and SNP-840, which are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email